A personalised sequencing approach for liquid biopsy-based detection of recurrent disease in early-…
A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2…
Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal…
Circulating tumor DNA (ctDNA) monitoring in breast cancer patients receiving neoadjuvant…
Circulating Tumour DNA (ctDNA) Detection and Dynamics in Patients with Early Breast Cancer (EBC):…
Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based…
ctDNA Dynamics in Early Stage Node Negative Non-small Cell Lung Cancers
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate…
Detection of early-stage breast cancer recurrence using a personalised liquid biopsy-based…
Evaluation of a tumor informed MRD assay with contrived breast cancer samples
Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular…
Liquid biopsies for residual disease and recurrence
Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous…
Liquid bIOpsy for miNimal rESidual diSease detection in Head and Neck Squamous Cell Carcinoma (…
Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (…
Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and…
Patient Discussion Guide
Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple…
Personalised circulating cell-free tumour DNA analysis for detection of minimal residual disease…
Personalized circulating tumor DNA (ctDNA) analysis in patients with recurrent/metastatic Head…
Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by…
RaDaR Bibliography
RaDaR Brochure
RaDaR Flyer
RaDaR for Breast Cancer
RaDaR for Colorectal Cancer
RaDaR for Head and Neck Cancer
RaDaR for Lung Cancer
RaDaR Pharma Brochure
RaDaR Requisition form
RaDaR Sample Reports
RaDaR Tissue and Specimen Requirements
Residual ctDNA after treatment predicts early relapse in patients with early stage NSCLC
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell…
Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in…
Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated…
How to order a RaDaR test
CLIENT SERVICES
NeoGenomics prides itself on its unparalleled customer support team. If you have questions regarding test information, specimen requirements, turnaround times, test add-on, and test results, please feel free to reach out to a Client Services Advocate at client.services@neogenomics.com or call 866.776.5907, option 3.
ONLINE ORDERING
Online Ordering streamlines and simplifies your test-ordering process into a single time-saving, easy-to-use experience.
PAPER ORDER FORMS
Complete a RaDaR test requisition form.
New to NeoGenomics? Call the NeoGenomics Client Services team at 866.776.5907 and press 3 to set up an account.
Get started with RaDaR
Contact us to order a RaDaR test.